Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Oocyte-based screening of cytokinesis inhibitors and identification of pectenotoxin-2 that induces Bim/Bax-mediated apoptosis in p53-deficient tumors

Abstract

In this study, we demonstrate that a loss of p53 sensitizes tumor cells to actin damage. Using a novel oocyte-based screening system, we identified natural compounds that inhibit cytokinesis. Among these, pectenotoxin-2 (PTX-2), which was first identified as a cytotoxic entity in marine sponges, which depolymerizes actin filaments, was found to be highly effective and more potent to activate an intrinsic pathway of apoptosis in p53-deficient tumor cells compared to those with functional p53 both in vitro and in vivo. Other agents that depolymerize or knot actin filaments were also found to be toxic to p53-deficient tumors. In p53-deficient cells, PTX-2 triggers apoptosis through mitochondrial dysfunction, and this is followed by the release of proapoptotic factors and caspase activation. Furthermore, we observed Bax activation and Bim induction only in p53-deficient cells after PTX-2 treatment. RNA interference of either Bim or Bax resulted in the inhibition of caspases and apoptosis induced by PTX-2. However, the small interfering RNAs (SiRNA) of Bim blocked a conformational change of Bax, but Bax SiRNA did not affect Bim expression. Therefore, these results suggest that Bim triggers apoptosis by activating Bax in p53-deficient tumors upon actin damage, and that actin inhibitors may be potent chemotherapeutic agents against p53-deficient tumors.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Bidere N, Lorenzo HK, Carmona S, Laforge M, Harper F, Dumont C and Senik A . (2003). J. Biol. Chem., 278, 31401–31411.

  • Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM and Strasser A . (1999). Science, 286, 1735–1738.

  • Chae HD, Yun J, Bang YJ and Shin DY . (2004). Oncogene, 23, 4084–4088.

  • Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T and Korsmeyer SJ . (2001). Mol. Cell., 8, 705–711.

  • Choi T, Aoki F, Mori M, Yamashita M, Nagahama Y and Kohmoto K . (1991). Development, 113, 789–795.

  • Debernardis D, Sire E, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D’Incalci M and Broggini M . (1997). Cancer Res., 57, 870–874.

  • Draisci R, Lucentini L, Giannetti L, Boria P and Poletti R . (1996). Toxicon, 34, 923–935.

  • el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . (1993). Cell, 75, 817–825.

  • Fan S, Cherney B, Reinhold W, Rucker K and O’Connor P . (1998). Clin. Cancer Res., 4, 1047–1054.

  • Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace Jr AJ, Magrath I, Kohn KW and O’Connor PM . (1994). Cancer Res., 54, 5824–5830.

  • Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R and Prives C . (1992). Nature, 358, 83–86.

  • Graham FL and van der Eb AJ . (1973). Virology, 54, 536–539.

  • Green DR and Reed JC . (1998). Science, 281, 1309–1312.

  • Gross A, McDonnell JM and Korsmeyer SJ . (1999). Genes Dev., 13, 1899–1911.

  • Gu Y, Turck CW and Morgan DO . (1993). Nature, 366, 707–710.

  • Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ . (1993). Cell, 75, 805–816.

  • Hollstein M, Sidransky D, Vogelstein B and Harris CC . (1991). Science, 253, 49–53.

  • Hori M, Matsuura Y, Yoshimoto R, Ozaki H, Yasumoto T and Karaki H . (1999). Nippon Yakurigaku Zasshi, 114 (Suppl 1), 225P–229P.

  • Jung MS, Yun J, Chae HD, Kim JM, Kim SC, Choi TS and Shin DY . (2001). Oncogene, 20, 5818–5825.

  • Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B . (1992). Science, 256, 827–830.

  • Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T . (1994). Science, 266, 807–810.

  • Lowe SW, Ruley HE, Jacks T and Housman DE . (1993). Cell, 74, 957–967.

  • Masui Y . (1996). Prog. Cell. Cycle Res., 2, 1–13.

  • McIlwrath AJ, Vasey PA, Ross GM and Brown R . (1994). Cancer Res., 54, 3718–3722.

  • Nechushtan A, Smith CL, Hsu Y-T and Youle RJ . (1999). EMBO J., 18, 2330–2341.

  • O’Connor P, Jackman J, Bae I, Myers T, Fan S, Mutoh M, Scudiero D, Monks A, Sausville E, Weinstein J, Friend S, Fornace Jr A and Kohn K . (1997). Cancer Res., 57, 4285–4300.

  • Park M, Chae HD, Yun J, Jung M, Kim YS, Kim SH, Han MH and Shin DY . (2000). Cancer Res., 60, 542–545.

  • Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J, Muthuswamy SK and Brugge JS . (2003). Nat. Cell. Biol., 5, 733–740.

  • Scorrano L and Korsmeyer SJ . (2003). Biochem. Biophys. Res. Commun., 304, 437–444.

  • Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang H-G, Reed JC, Nicholson DW, Alnemri ES, Green DR and Martin SJ . (1999). J. Cell Biol., 144, 281–292.

  • Spector I, Braet F, Shochet NR and Bubb MR . (1999). Microsc. Res. Tech., 47, 18–37.

  • Trielli M, Andreassen P, Lacroix F and Margolis R . (1996). J. Cell Biol., 135, 689–700.

  • Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN . (1998). Cell, 93, 705–716.

  • Valavanis C, Hu Y, Yang Y, Osborne BA, Chouaib S, Greene L, Ashwell JD and Schwartz LM . (2001). Methods Cell. Biol., 66, 417–436.

  • Vaux DL and Korsmeyer SJ . (1999). Cell, 96, 245–254.

  • Vousden KH and Lu X . (2002). Nat. Rev. Cancer, 2, 594–604.

  • Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW and Galloway DA . (1996). Nat. Med., 2, 72–79.

  • Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D . (1993). Nature, 366, 701–704.

  • Yamaguchi H, Bhalla K and Wang HG . (2003). Cancer Res., 63, 1483–1489.

  • Yun J, Chae HD, Choi T-S, Kim E-H, Bang Y-J, Chung J-K, Choi K-S, Mantovani R and Shin DY . (2003). J. Biol. Chem. M305178200.

  • Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH and Shin DY . (1999). J. Biol. Chem., 274, 29677–29682.

  • Zambetti G, Bargonetti J, Walker K, Prives C and Levine A . (1992). Genes Dev., 6, 1143–1152.

Download references

Acknowledgements

We thank Dr K Homma for his critical reading of the manuscript and the National Research Laboratory Program of the Korean Ministry of Science, the Molecular Aging Research Center, and National Cancer Control Program for financially supporting this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Deug Y Shin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chae, HD., Choi, TS., Kim, BM. et al. Oocyte-based screening of cytokinesis inhibitors and identification of pectenotoxin-2 that induces Bim/Bax-mediated apoptosis in p53-deficient tumors. Oncogene 24, 4813–4819 (2005). https://doi.org/10.1038/sj.onc.1208640

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208640

Keywords

This article is cited by

Search

Quick links